Gene D Park

US Patent:

D462150, Aug 27, 2002

Filed:

Apr 11, 2001

Appl. No.:

29/140103

Inventors:

James E. Rader - Pleasanton CA
Scott T. Haubrich - San Leandro CA
Richard Porticos - Los Altos CA
Gene Park - Oakland CA

Assignee:

The Clorox Company - Oakland CA

International Classification:

0402

US Classification:

D32 40

US Patent:

D486616, Feb 10, 2004

Filed:

Apr 11, 2001

Appl. No.:

29/140155

Inventors:

Michael J. Hall - South San Francisco CA
James E. Rader - Pleasanton CA
Robert W. Flagler - Pleasanton CA
Scott T. Haubrich - San Leandro CA
Karen S. Hefter - San Ramon CA
Richard Porticos - Los Altos CA
Gene Park - Oakland CA
Douglas Minkler - Livermore CA
David J. Sayler - Portland OR
Eric Y. Park - Portland OR

Assignee:

The Clorox Company - Oakland CA

International Classification:

0401

US Classification:

D32 45

US Patent:

D503253, Mar 22, 2005

Filed:

Jul 10, 2003

Appl. No.:

29/186188

Inventors:

James E. Rader - Pleasanton CA, US
Scott T. Haubrich - San Leandro CA, US
Richard Porticos - Los Altos CA, US
Gene Park - Oakland CA, US

Assignee:

The Clorox Company - Oakland CA

International Classification:

0401

US Classification:

D32 40

US Patent:

8017140, Sep 13, 2011

Filed:

May 21, 2007

Appl. No.:

11/804997

Inventors:

Syed Faiyaz Ahmed Hossainy - Fremont CA, US
Gordon Stewart - San Francisco CA, US
Deborah Kilpatrick - Los Altos CA, US
Jeffrey Ellis - San Francisco CA, US
Gene Park - Oakland CA, US
Gina Zhang - Fremont CA, US
Paul Consigny - San Jose CA, US
Yiwen Tang - San Jose CA, US

Assignee:

Advanced Cardiovascular System, Inc. - Santa Clara CA

International Classification:

A61F 13/00
A61F 2/00
A61K 9/14

US Classification:

424422, 424423, 424426, 424486

Abstract:

Drug-delivery stents capable of providing release of two or more drugs such as everolimus and estradiol are provided. The stents can be used for treating a disease such as restenosis and vulnerable plaque.

US Patent:

8435550, May 7, 2013

Filed:

Aug 13, 2008

Appl. No.:

12/191209

Inventors:

Jin Cheng - San Jose CA, US
Stephen Dugan - Berkeley CA, US
Gordon Stewart - San Francisco CA, US
Gina Zhang - Calabasas CA, US
Nancy Kirsten - Tucson AZ, US
Paul Consigny - San Jose CA, US
Christopher Feezor - San Jose CA, US
Gene Park - Santa Rosa CA, US
Wouter Roorda - Palo Alto CA, US
Syed F. A. Hossainy - Fremont CA, US

Assignee:

Abbot Cardiovascular Systems Inc. - Santa Clara CA

International Classification:

A61F 2/02

US Classification:

424423

Abstract:

A drug-delivery system is provided including at least 100 μg of everolimus and clobetasol, such that the ratio of everolimus to clobetasol is at least 10:1 (w/w) or the amount of everolimus by weight is at least 10 times more than clobetasol. The system can be a stent. Also provided a method of treating restenosis or vulnerable plaque of a blood vessel, the method includes locally administering to a patient a first drug selected from a group consisting of rapamycin (sirolimus), Biolimus A9, deforolimus, AP23572, tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethylrapamycin (everolimus), 40-O-(3-hydroxy)propylrapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethylrapamycin, 40-O-tetrazolylrapamycin and 40-epi-(N1-tetrazolyl)rapamycin, and locally administering to a patient a second drug consisting of clobetasol, wherein the minimum amount of the first drug that is locally administered is 100 μg, and wherein the ratio of the first drug to the second drug is, for example, 10:1 to 100:1 (w/w).

US Patent:

20030180083, Sep 25, 2003

Filed:

Jan 24, 2003

Appl. No.:

10/351293

Inventors:

Michael Hall - South San Francisco CA, US
James Rader - Pleasanton CA, US
Boli Zhou - Tualatin OR, US
Karen Hefter - San Ramon CA, US
David Sayler - Portland OR, US
Eric Park - Portland OR, US
Robert Flagler - Pleasanton CA, US
Scott Haubrich - San Leandro CA, US
Shumanta MItra - Dublin CA, US
Richard Porticos - Los Altos CA, US
Gene Park - Pleasanton CA, US

International Classification:

A46B011/00
A47L013/22

US Classification:

401/140000, 401/270000, 401/278000, 401/138000

Abstract:

A cleaning pad for use on a cleaning system in which cleaning fluid or other liquid is dispensed onto a surface in front of a cleaning head portion, the cleaning pad comprising a central absorbent and scrubbing portion, a back edge portion for removably attaching the cleaning pad to the cleaning head portion, and a front edge portion for removably attaching the cleaning pad to the cleaning head portion, the front edge portion having a notch thereon, thereby allowing attachment of the cleaning pad to the cleaning head portion such that cleaning or other fluid can be dispensed from the cleaning head portion onto a surface in front of the cleaning head portion without interference by the cleaning pad.

US Patent:

20050287184, Dec 29, 2005

Filed:

Jun 29, 2004

Appl. No.:

10/881540

Inventors:

Syed Hossainy - Fremont CA, US
Gordon Stewart - San Francisco CA, US
Deborah Kilpatrick - Los Altos CA, US
Jeffrey Ellis - San Francisco CA, US
Gene Park - Oakland CA, US
Gina Zhang - Fremont CA, US
Paul Consigny - San Jose CA, US
Yiwen Tang - San Jose CA, US

International Classification:

A61K031/56
A61K031/4745

US Classification:

424423000, 514171000, 514291000

Abstract:

Drug-delivery stents capable of providing release of two or more drugs such as everolimus and estradiol are provided. The stents can be used for treating a disease such as restenosis and vulnerable plaque.

US Patent:

58799206, Mar 9, 1999

Filed:

Dec 22, 1995

Appl. No.:

8/577894

Inventors:

Douglas A. Dale - Pacifica CA
Alfred L. Gaertner - San Bruno CA
Gene Park - Cincinnati OH
Nathaniel T. Becker - Burlingame CA

Assignee:

Genencor International, Inc. - Rochester NY

International Classification:

C12N 998
C12N 1108
C11D 1000
D06M 1600

US Classification:

435187

Abstract:

A granular enzyme composition is produced having reduced tendency to form dust and leave a residue, and improved stability and delayed release characteristics. The composition has a core, optionally coated with a vinyl polymer, a layer containing an enzyme and a vinyl polymer and optionally a plasticizer or anti-agglomeration agent, and an outer coating containing a polymer and optionally a low residue pigment and/or lubricant. Preferably, the core is a salt or sugar nonpareil, the vinyl polymer coating the core is polyvinyl alcohol and most preferably partially hydrolyzed polyvinyl alcohol, the vinyl polymer in the enzyme layer is polyvinyl pyrrolidone, and the polymer of the outer coating is polyvinyl pyrrolidone, polyvinyl alcohol which may be partially hydrolyzed, polyethylene glycol or mixtures thereof such as a mixture of polyvinyl pyrrolidone and polyvinyl alcohol or a mixture of polyvinyl pyrrolidone and polyethylene glycol. Preferably, the pigment is titanium dioxide and the lubricant is a nonionic or anionic surfactant such as a linear primary alcohol of a 9-15 carbon atom chain length alkane or alkene or an ethoxylate or ethoxysulfate derivative thereof. The enzyme can be a protease, amylase, lipase, cellulase, xylanase, oxidase, peroxidase or mixtures thereof.